Drug profile

The FDA adverse-event record for Blood Transfusion

70 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Blood Transfusion. See the species affected, top reactions, and outcomes below.

70
adverse-event reports
54.3%
death-coded share
Dog
most-reported species
22
Immune mediated haemolytic anaemia - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
70
Total Reports
38
Deaths Reported
54.3%
Death Rate

Active Ingredients

Blood Transfusion

Administration Routes

IntravenousUnknownParenteral

Species Affected

Dog 54
Cat 16

Most Affected Breeds

Domestic Shorthair 7
Retriever - Labrador 5
Shepherd Dog - German 4
Domestic Longhair 4
Dog (unknown) 4
Chihuahua 3
Shih Tzu 3
Shepherd Dog - Australian 2
Crossbred Canine/dog 2
Terrier - Jack Russell 2

Most Reported Reactions

Immune mediated haemolytic anaemia 22
Death by euthanasia 20
Anaemia NOS 18
Pale mucous membrane 17
Vomiting 17
Decreased packed cell volume (PCV) 17
Diarrhoea 16
Death 15
Leucocytosis NOS 14
Lethargy (see also Central nervous system depression in Neurological) 14
Lethargy (see also Central nervous system depression in 'Neurological') 13
Other abnormal test result NOS 12

Outcome Breakdown

Euthanized
23 (32.9%)
Died
15 (21.4%)
Ongoing
12 (17.1%)
Outcome Unknown
10 (14.3%)
Recovered/Normal
10 (14.3%)

Blood Transfusion Adverse Event Insights

70 reports name Blood Transfusion; 38 recorded a death outcome (54.3% of reported events, not a population-level mortality rate). Active ingredient: Blood Transfusion. Administration routes: Intravenous, Unknown, Parenteral.

By species: Dog (54 reports), Cat (16 reports). By breed: Domestic Shorthair (7), Retriever - Labrador (5), Shepherd Dog - German (4).

Leading clinical signs: Immune mediated haemolytic anaemia (22), Death by euthanasia (20), Anaemia NOS (18), Pale mucous membrane (17). Outcome, 70 coded reports: Euthanized leads at 32.9%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.